Foehr W. Matthew's most recent trade in Viking Therapeutics Inc was a trade of 20,786 Common Stock, par value $0.00001 per share done at an average price of $8 . Disclosure was reported to the exchange on April 11, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Viking Therapeutics Inc | Matthew W. Foehr | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.00 per share. | 11 Apr 2025 | 20,786 | 132,036 (0%) | 0% | 8 | 166,288 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | Matthew W. Foehr | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Apr 2025 | 20,786 | 0 | - | - | Stock Option (Right to Buy) | |
| OmniAb Inc | Matthew W. Foehr | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Apr 2025 | 36,458 | 3,815,618 | - | 0 | Common Stock | |
| OmniAb Inc | Matthew W. Foehr | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Apr 2025 | 36,458 | 310,930 | - | - | Restricted Stock Units | |
| OmniAb Inc | Matthew W. Foehr | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 2.00 per share. | 07 Apr 2025 | 19,382 | 3,796,236 | - | 2 | 38,764 | Common Stock |
| OmniAb Inc | Matthew W. Foehr | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2025 | 1,050,000 | 1,050,000 | - | - | Stock Option (right to buy) | |
| OmniAb Inc | Matthew W. Foehr | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2025 | 175,000 | 347,388 | - | - | Restricted Stock Units | |
| OmniAb Inc | Matthew W. Foehr | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2025 | 36,458 | 3,812,646 | - | - | Common Stock | |
| OmniAb Inc | Matthew W. Foehr | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2025 | 36,458 | 172,388 | - | - | Restricted Stock Units | |
| OmniAb Inc | Matthew W. Foehr | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2025 | 26,549 | 3,776,188 | - | - | Common Stock | |
| OmniAb Inc | Matthew W. Foehr | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2025 | 26,549 | 208,846 | - | - | Restricted Stock Units | |
| OmniAb Inc | Matthew W. Foehr | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 3.67 per share. | 15 Feb 2025 | 19,522 | 3,779,160 | - | 3.7 | 71,646 | Common Stock |
| OmniAb Inc | Matthew W. Foehr | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 3.68 per share. | 15 Feb 2025 | 13,964 | 3,798,682 | - | 3.7 | 51,388 | Common Stock |
| OmniAb Inc | Matthew W. Foehr | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jan 2025 | 77,003 | 3,791,450 | - | 0 | Common Stock | |
| OmniAb Inc | Matthew W. Foehr | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 3.24 per share. | 17 Jan 2025 | 41,811 | 3,749,639 | - | 3.2 | 135,468 | Common Stock |
| Viking Therapeutics Inc | Matthew W. Foehr | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 18,800 | 18,800 | - | - | Stock Option (Right to Buy) | |
| OmniAb Inc | Matthew W. Foehr | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Dec 2024 | 26,555 | 235,395 | - | - | Restricted Stock Units | |
| OmniAb Inc | Matthew W. Foehr | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Dec 2024 | 26,555 | 3,728,081 | - | - | Common Stock | |
| OmniAb Inc | Matthew W. Foehr | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 4.13 per share. | 07 Dec 2024 | 13,634 | 3,714,447 | - | 4.1 | 56,308 | Common Stock |
| OmniAb Inc | Matthew W. Foehr | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.75 per share. | 25 Nov 2024 | 68,360 | 3,698,600 | - | 3.8 | 256,350 | Common Stock |
| OmniAb Inc | Matthew W. Foehr | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Nov 2024 | 68,360 | 396,484 | - | - | Stock Option (right to buy) | |
| OmniAb Inc | Matthew W. Foehr | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.68 per share. | 25 Nov 2024 | 31,074 | 3,630,240 | - | 3.7 | 114,352 | Common Stock |
| OmniAb Inc | Matthew W. Foehr | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Nov 2024 | 31,074 | 155,371 | - | - | Stock Option (right to buy) | |
| OmniAb Inc | Matthew W. Foehr | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.75 per share. | 27 Jun 2024 | 41,015 | 3,599,166 | - | 3.7 | 153,806 | Common Stock |
| OmniAb Inc | Matthew W. Foehr | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Jun 2024 | 41,015 | 464,844 | - | - | Stock Option (right to buy) | |
| OmniAb Inc | Matthew W. Foehr | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Jun 2024 | 18,644 | 186,445 | - | - | Stock Option (right to buy) | |
| OmniAb Inc | Matthew W. Foehr | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.68 per share. | 27 Jun 2024 | 18,644 | 3,558,151 | - | 3.7 | 68,610 | Common Stock |
| OmniAb Inc | Matthew W. Foehr | Director, President and CEO | Purchase of securities on an exchange or from another person at price $ 4.42 per share. | 24 May 2024 | 240,000 | 3,536,665 | - | 4.4 | 1,059,840 | Common Stock |
| OmniAb Inc | Matthew W. Foehr | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Apr 2024 | 36,458 | 261,950 | - | - | Restricted Stock Units | |
| OmniAb Inc | Matthew W. Foehr | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Apr 2024 | 36,458 | 3,188,874 | - | - | Common Stock | |
| OmniAb Inc | Matthew W. Foehr | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.31 per share. | 07 Apr 2024 | 18,477 | 3,170,397 | - | 5.3 | 98,113 | Common Stock |
| OmniAb Inc | Matthew W. Foehr | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Mar 2024 | 150,391 | 505,859 | - | - | Stock Option (right to buy) | |
| OmniAb Inc | Matthew W. Foehr | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.75 per share. | 27 Mar 2024 | 150,391 | 3,152,416 | - | 3.7 | 563,966 | Common Stock |
| OmniAb Inc | Matthew W. Foehr | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Mar 2024 | 93,222 | 205,089 | - | - | Stock Option (right to buy) | |
| OmniAb Inc | Matthew W. Foehr | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.68 per share. | 27 Mar 2024 | 93,222 | 3,002,025 | - | 3.7 | 343,057 | Common Stock |
| OmniAb Inc | Matthew W. Foehr | Director, President and CEO | Purchase of securities on an exchange or from another person at price $ 5.19 per share. | 22 Mar 2024 | 225,000 | 2,908,803 | - | 5.2 | 1,167,750 | Common Stock |
| OmniAb Inc | Foehr Matthew W. | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 656,250 | 656,250 | - | - | Stock Option (right to buy) | |
| OmniAb Inc | Matthew Foehr W. | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 109,375 | 298,408 | - | - | Restricted Stock Units | |
| OmniAb Inc | Matthew W. Foehr | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2024 | 26,558 | 2,697,263 | - | - | Common Stock | |
| OmniAb Inc | Foehr Matthew W. | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2024 | 26,558 | 189,033 | - | - | Restricted Stock Units | |
| OmniAb Inc | Foehr Matthew W. | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.54 per share. | 15 Feb 2024 | 13,460 | 2,683,803 | - | 5.5 | 74,568 | Common Stock |
| OmniAb Inc | Matthew Foehr W. | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2024 | 10,770 | 215,591 | - | - | Restricted Stock Units | |
| OmniAb Inc | Matthew W. Foehr | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2024 | 10,770 | 2,676,164 | - | - | Common Stock | |
| OmniAb Inc | Matthew Foehr W. | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.54 per share. | 15 Feb 2024 | 5,459 | 2,670,705 | - | 5.5 | 30,243 | Common Stock |
| OmniAb Inc | Foehr W. Matthew | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2024 | 33,173 | 2,678,615 | - | - | Common Stock | |
| OmniAb Inc | W. Matthew Foehr | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2024 | 33,173 | 226,361 | - | - | Restricted Stock Units | |
| Viking Therapeutics Inc | Matthew W. Foehr | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 32,000 | 32,000 | - | - | Stock Option (Right to Buy) | |
| OmniAb Inc | Matthew Foehr W. | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.25 per share. | 02 Jan 2024 | 13,221 | 2,665,394 | - | 6.2 | 82,631 | Common Stock |
| OmniAb Inc | Matthew W. Foehr | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 5.05 per share. | 12 Dec 2023 | 200,000 | 2,645,442 | - | 5.1 | 1,010,000 | Common Stock |
| OmniAb Inc | W. Foehr Matthew | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Dec 2023 | 26,556 | 2,454,626 | - | - | Common Stock | |
| OmniAb Inc | W. Matthew Foehr | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Dec 2023 | 26,556 | 259,534 | - | - | Restricted Stock Units | |
| OmniAb Inc | Foehr W. Matthew | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.85 per share. | 07 Dec 2023 | 9,184 | 2,445,442 | - | 4.8 | 44,542 | Common Stock |
| OmniAb Inc | Matthew W. Foehr | Director, President and CEO | Purchase of securities on an exchange or from another person at price $ 5.48 per share. | 14 Aug 2023 | 45,000 | 2,332,919 | - | 5.5 | 246,600 | Common Stock |
| OmniAb Inc | Matthew W. Foehr | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 4.52 per share. | 09 Jun 2023 | 115,000 | 2,574,009 | - | 4.5 | 519,800 | Common Stock |
| OmniAb Inc | Matthew W. Foehr | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 3.40 per share. | 12 May 2023 | 440,000 | 2,438,414 | - | 3.4 | 1,496,000 | Common Stock |
| OmniAb Inc | Matthew W. Foehr | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Apr 2023 | 656,250 | 656,250 | - | - | Stock Option | |
| OmniAb Inc | Matthew W. Foehr | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Apr 2023 | 109,375 | 1,998,414 | - | 0 | Common Stock | |
| OmniAb Inc | Matthew W. Foehr | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.80 per share. | 15 Feb 2023 | 9,184 | 1,896,941 | - | 3.8 | 34,899 | Common Stock |
| OmniAb Inc | Matthew W. Foehr | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.80 per share. | 15 Feb 2023 | 4,177 | 1,889,039 | - | 3.8 | 15,873 | Common Stock |
| OmniAb Inc | Matthew W. Foehr | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.80 per share. | 15 Feb 2023 | 3,725 | 1,893,216 | - | 3.8 | 14,155 | Common Stock |
| Viking Therapeutics Inc | Matthew W. Foehr | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 22,000 | 22,000 | - | - | Stock Option (Right to Buy) | |
| OmniAb Inc | Matthew W. Foehr | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Nov 2022 | 1,431,618 | 3,296,665 | - | - | Common Stock | |
| OmniAb Inc | Matthew W. Foehr | Director, CLO & Secretary | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Nov 2022 | 212,362 | 0 | - | - | Common Stock | |
| OmniAb Inc | Matthew W. Foehr | Director, CLO & Secretary | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Nov 2022 | 60,878 | 0 | - | - | Stock Option | |
| OmniAb Inc | Matthew W. Foehr | Director, CLO & Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Nov 2022 | 60,878 | 60,878 | - | - | Stock Option | |
| OmniAb Inc | Matthew W. Foehr | Director, CLO & Secretary | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Nov 2022 | 55,222 | 0 | - | - | Stock Option | |
| OmniAb Inc | Matthew W. Foehr | Director, CLO & Secretary | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Nov 2022 | 35,258 | 0 | - | - | Stock Option | |
| Ligand Pharmaceuticals, In... | Matthew W. Foehr | Former Executive Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Nov 2022 | 34,214 | 0 | - | - | Employee Stock Option (right to buy) | |
| OmniAb Inc | Matthew W. Foehr | Director, CLO & Secretary | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Nov 2022 | 29,861 | 0 | - | - | Stock Option | |
| OmniAb Inc | Matthew W. Foehr | Director, CLO & Secretary | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Nov 2022 | 29,012 | 0 | - | - | Stock Option | |
| OmniAb Inc | Matthew W. Foehr | Director, CLO & Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Nov 2022 | 26,193 | 212,362 | - | 0 | Common Stock | |
| OmniAb Inc | Matthew W. Foehr | Director, CLO & Secretary | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Nov 2022 | 22,660 | 0 | - | - | Stock Option | |
| OmniAb Inc | Matthew W. Foehr | Director, CLO & Secretary | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Nov 2022 | 21,271 | 0 | - | - | Stock Option | |
| Ligand Pharmaceuticals, In... | Matthew W. Foehr | Former Executive Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Nov 2022 | 20,304 | 162,187 (0%) | 0% | - | Common Stock | |
| OmniAb Inc | Matthew W. Foehr | Director, CLO & Secretary | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Nov 2022 | 17,711 | 0 | - | - | Stock Option | |
| OmniAb Inc | Matthew W. Foehr | Director, CLO & Secretary | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Nov 2022 | 11,475 | 0 | - | - | Stock Option | |
| Ligand Pharmaceuticals, In... | Matthew W. Foehr | President and COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2022 | 9,137 | 182,491 (1%) | 0% | 0 | Common Stock | |
| Ligand Pharmaceuticals, In... | Matthew W. Foehr | President and COO | Purchase of securities on an exchange or from another person at price $ 82.76 per share. | 13 May 2022 | 2,500 | 173,354 (1%) | 0% | 82.8 | 206,910 | Common Stock |
| Ligand Pharmaceuticals, In... | Matthew W. Foehr | President and COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 May 2022 | 34,214 | 34,214 | - | - | Employee Stock Option (right to buy) | |
| Viking Therapeutics Inc | Matthew W. Foehr | Director | Purchase of securities on an exchange or from another person at price $ 2.47 per share. | 02 May 2022 | 45,000 | 111,250 (0%) | 0% | 2.5 | 111,195 | Common Stock, par value $0.00001 per share |
| Ligand Pharmaceuticals, In... | Matthew W. Foehr | President and COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 123.68 per share. | 15 Feb 2022 | 1,234 | 173,166 (1%) | 0% | 123.7 | 152,621 | Common Stock |
| Ligand Pharmaceuticals, In... | Matthew W. Foehr | President and COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 123.68 per share. | 15 Feb 2022 | 1,222 | 171,944 (1%) | 0% | 123.7 | 151,137 | Common Stock |
| Ligand Pharmaceuticals, In... | Matthew W. Foehr | President and COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 123.68 per share. | 15 Feb 2022 | 1,090 | 170,854 (1%) | 0% | 123.7 | 134,811 | Common Stock |
| Viking Therapeutics Inc | Matthew W. Foehr | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 22,000 | 22,000 | - | - | Stock Option (Right to Buy) | |
| Ligand Pharmaceuticals, In... | Matthew W. Foehr | President and COO | Sale of securities on an exchange or to another person at price $ 163.02 per share. | 11 Nov 2021 | 11,160 | 166,525 (1%) | 0% | 163.0 | 1,819,255 | Common Stock |
| Ligand Pharmaceuticals, In... | Matthew W. Foehr | President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.92 per share. | 11 Nov 2021 | 11,160 | 177,685 (1%) | 0% | 21.9 | 244,627 | Common Stock |
| Ligand Pharmaceuticals, In... | Matthew W. Foehr | President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Nov 2021 | 11,160 | 0 | - | - | Employee Stock Option (right to buy) | |
| Ligand Pharmaceuticals, In... | Matthew W. Foehr | President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 100.38 per share. | 11 Nov 2021 | 1,028 | 166,525 (1%) | 0% | 100.4 | 103,191 | Common Stock |
| Ligand Pharmaceuticals, In... | Matthew W. Foehr | President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Nov 2021 | 1,028 | 24,348 | - | - | Employee Stock Option (right to buy) | |
| Ligand Pharmaceuticals, In... | Matthew W. Foehr | President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Aug 2021 | 8,840 | 11,160 | - | - | Employee Stock Option (right to buy) | |
| Ligand Pharmaceuticals, In... | Matthew W. Foehr | President and COO | Sale of securities on an exchange or to another person at price $ 109.67 per share. | 04 Aug 2021 | 8,840 | 164,355 (0%) | 0% | 109.7 | 969,507 | Common Stock |
| Ligand Pharmaceuticals, In... | Matthew W. Foehr | President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.92 per share. | 04 Aug 2021 | 8,840 | 173,195 (1%) | 0% | 21.9 | 193,773 | Common Stock |
| Ligand Pharmaceuticals, In... | Matthew W. Foehr | President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Aug 2021 | 1,142 | 25,938 | - | - | Employee Stock Option (right to buy) | |
| Ligand Pharmaceuticals, In... | Matthew W. Foehr | President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 85.79 per share. | 04 Aug 2021 | 1,142 | 165,497 (1%) | 0% | 85.8 | 97,972 | Common Stock |
| Viking Therapeutics Inc | Matthew W. Foehr | Director | Purchase of securities on an exchange or from another person at price $ 5.69 per share. | 10 Jun 2021 | 20,000 | 66,250 (0%) | 0% | 5.7 | 113,800 | Common Stock, par value $0.00001 per share |
| Ligand Pharmaceuticals, In... | Matthew W. Foehr | President and COO | Gift of securities by or to the insider at price $ 0.00 per share. | 28 May 2021 | 2,500 | 162,600 (0%) | 0% | 0 | Common Stock | |
| Ligand Pharmaceuticals, In... | Matthew W. Foehr | President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 56.26 per share. | 28 May 2021 | 1,755 | 164,355 (0%) | 0% | 56.3 | 98,736 | Common Stock |
| Ligand Pharmaceuticals, In... | Matthew W. Foehr | President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 May 2021 | 1,755 | 40,358 | - | - | Employee Stock Option (right to buy) | |
| Viking Therapeutics Inc | Matthew W. Foehr | Director | 22 Mar 2021 | 20,000 | 0 | - | - | Warrants (Right to Buy) | ||
| Viking Therapeutics Inc | Matthew W. Foehr | Director | 22 Mar 2021 | 20,000 | 46,250 (0%) | 0% | 1.5 | 30,000 | Common Stock, par value $0.00001 per share | |
| Ligand Pharmaceuticals, In... | Matthew W. Foehr | President and COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 172.46 per share. | 15 Feb 2021 | 1,235 | 166,322 (1%) | 0% | 172.5 | 212,988 | Common Stock |